Floatz logo

ik-175

Bladder Disease

Ikena OncologyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Bladder Disease cohort.

Asset / SponsorPhaseRating
Tamsulosin
Centre Hospitalier Universitaire de Nīmes
Phase 3BB
Cranberry
Rennes University Hospital
Phase 3B
Oxybutynin
University of California, Davis
Phase 3B
Oxybutynin Transdermal Patch
University of California, Davis
Phase 3B
Alfuzosin
Nova Scotia Health Authority
Phase 2/3CCC

View all 10 →

Same molecule, other indications

ik-175 is also rated in:

Bladder Urothelial CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
urinary bladder cancerDormant
CC
Indicative ·
47 / 100
View asset →
urothelial neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →